💉
BNT162 Vaccine
9 articles analyzed — Average score : 41/100
Grade distribution
Authors' conclusions
Articles
B
Mostly reliable (64/100)
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. Positive
Polack FP et al.·New England Journal of Medicine·Dec 2020
C
Nuanced (51/100)
Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months. Mixed
Levin EG et al.·The New England Journal of Medicine·Oct 2021
C
Nuanced (50/100)
Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. Mixed
Andrews N et al.·The New England journal of medicine·Apr 2022
C
Nuanced (49/100)
Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel. Positive
Mevorach Dror et al.·The New England Journal of Medicine·Oct 2021
C
Nuanced (46/100)
Impact of original, B.1.1.7, and B.1.351/P.1 SARS-CoV-2 lineages on vaccine effectiveness of two doses of COVID-19 mRNA vaccines: Results from a nationwide case-control study in France. Positive
Charmet T et al.·Lancet Regional Health – Europe·Jul 2021
D
Unreliable (31/100)
Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021. Positive
Oster ME et al.·JAMA·Jan 2022
D
Unreliable (30/100)
Surveillance for Adverse Events After COVID-19 mRNA Vaccination. Negative
Klein NP et al.·JAMA·Oct 2021
D
Unreliable (27/100)
Association Between BNT162b2 Vaccination and Long COVID After Infections Not Requiring Hospitalization in Health Care Workers. Inconclusive
Azzolini E et al.·JAMA·Aug 2022
E
Not reliable (25/100)
Protection against Covid-19 by BNT162b2 Booster across Age Groups. Positive
Bar-On YM et al.·N Engl J Med·Jan 2021